Christian Thomas Ruff, MD, MPH
November 26th, 2013
Edoxaban and the Changing Landscape of Novel Anticoagulants for Atrial Fibrillation
Christian Thomas Ruff, MD, MPH
Christian Thomas Ruff, a coauthor of the ENGAGE AF-TIMI 48 trial of edoxaban versus warfarin in patients with atrial fibrillation, discusses the future of novel anticoagulants.
January 17th, 2013
Revisiting Novel Anticoagulants in Atrial Fibrillation
John Ryan, MD and Christian Thomas Ruff, MD, MPH
Two experts discuss the evolving landscape of novel anticoagulants for patients with AF. Do you agree with their perspectives? What questions do you have? What has your experience taught you?
November 28th, 2011
Roundtable: Two Trials, Two Anticoagulants, Many Implications
Samuel Goldhaber, MD, Elaine Marie Hylek, MD, MPH and Christian Thomas Ruff, MD, MPH
Three experts weigh in on findings from the ATLAS ACS 2-TIMI 51 and ADOPT trials.
NEJM Journal Watch — Recent Cardiology Articles- Strategies and Criteria for the Diagnosis and Management of Myocarditis
- Sex-Based Disparity in CABG Outcomes: Are We Moving Toward Parity?
- Can Genetic and Social Risk Scores Improve Cardiac Risk Prediction?
- Extensive Ablation vs. Pulmonary Vein Isolation in Persistent Atrial Fibrillation
- Can a Novel Stent Design Improve Long-Term Outcomes of Percutaneous Coronary Intervention?